Greg Yap brings nearly 20 years of operating experience from companies like Illumina and Ventana/Roche to his venture investing at Menlo Ventures, giving him hands-on knowledge of regulatory science, lab workflows, and clinical adoption that most VCs lack. He has created a formal "5 Ps of Therapeutics Investing" framework and leads Menlo's focus on companies where biology and advanced computation are combined from day one, rather than traditional therapeutics alone. Greg Yap brings nearly 20 years of operating experience from companies like Illumina and Ventana/Roche to his venture investing at Menlo Ventures, giving him hands-on knowledge of regulatory science, lab workflows, and clinical adoption that most VCs lack. He has created a formal "5 Ps of Therapeutics Investing" framework and leads Menlo's focus on companies where biology and advanced computation are combined from day one, rather than traditional therapeutics alone.